Literature DB >> 15505501

Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants.

Wei Wei1, Hongkui Jin, Zhi-Wu Chen, Thomas F Zioncheck, Anthony P C Yim, Guo-Wei He.   

Abstract

The role of the vascular endothelial growth factors (VEGF) receptors (KDR and Flt-1) and their characteristics in VEGF-induced vasodilation in human vessels is unclear. This study investigated the in vitro vasorelaxant effects of KDR-selective (KDR-SM) and Flt-1-selective mutants (Flt-1-SM) in the human internal mammary artery (IMA). IMA segments (n = 183) taken from 48 patients were studied in organ baths. The cumulative concentration (-12 to -8 log10M)-relaxation curves were established for VEGF, KDR-SM, Flt-1-SM, and placenta growth factor (PlGF) in the absence or presence of indomethacin (INDO, 7 microM), N-nitro-L-arginine (L-NNA, 300 microM), L-NNA + oxyhemoglobin (HbO, 20 microM), or INDO + L-NNA + HbO. The VEGF-induced relaxation was abolished in endothelium-denuded IMA. In the endothelium-intact vessel rings, VEGF (63.2 +/- 3.9%) induced significantly more (P < 0.001) relaxation than Flt-1-SM (28.5 +/- 4.3%, 95% CI 18.1-51.3%), and PlGF (26.0 +/- 4.7%, 95% CI 17.6-56.8%). The maximal relaxation induced by KDR-SM (53.0 +/- 4.0%) was only slightly less than that by VEGF (P = 0.075) but significantly more than that by Flt-1-SM (P = 0.001, 95% CI 7.8-41.1%). Pretreatment of INDO or L-NNA + HbO significantly (P < 0.001) inhibited the relaxation by VEGF (21.2 +/- 3.9% or 23.3 +/- 4.3%) and KDR-SM (9.8 +/- 8.2% or 10.1 +/- 17.8%). INDO + L-NNA + HbO completely inhibited the relaxation by VEGF, KDR-SM, or Flt-1-SM. KDR may be the dominant receptor in mediating the VEGF-mediated relaxation, which is regulated by both PGI2 and nitric oxide but probably not by endothelium-derived hyperpolarizing factor, in the human IMA. This study gives insight into the characteristics of the VEGF-mediated vasodilation and provides a scientific basis for potential clinical application of VEGF/KDR-SM in ischemic heart disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505501     DOI: 10.1097/00005344-200411000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Endothelial-derived hyperpolarization factor (EDHF) contributes to PlGF-induced dilation of mesenteric resistance arteries from pregnant rats.

Authors:  Maurizio Mandalà; Natalia Gokina; Carolyn Barron; George Osol
Journal:  J Vasc Res       Date:  2011-10-06       Impact factor: 1.934

2.  Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.

Authors:  Stephanie Debette; Sophie Visvikis-Siest; Ming-Huen Chen; Ndeye-Coumba Ndiaye; Ci Song; Anita Destefano; Radwan Safa; Mohsen Azimi Nezhad; Douglas Sawyer; Jean-Brice Marteau; Vanessa Xanthakis; Gerard Siest; Lisa Sullivan; Michele Pfister; Holly Smith; Seung-Hoan Choi; John Lamont; Lars Lind; Qiong Yang; Peter Fitzgerald; Erik Ingelsson; Ramachandran S Vasan; Sudha Seshadri
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

3.  Arterial grafts: clinical classification and pharmacological management.

Authors:  Guo-Wei He
Journal:  Ann Cardiothorac Surg       Date:  2013-07

Review 4.  Sunitinib side effects as surrogate biomarkers of efficacy.

Authors:  Christian Kollmannsberger
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

Review 5.  [Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

Authors:  D Sikic; N Meidenbauer; V Lieb; B Keck
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

6.  Placental growth factor is a potent vasodilator of rat and human resistance arteries.

Authors:  George Osol; Gerard Celia; Natalia Gokina; Carolyn Barron; Edward Chien; Maurizio Mandala; Leonid Luksha; Karolina Kublickiene
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-11       Impact factor: 4.733

7.  Skeletal myofiber VEGF regulates contraction-induced perfusion and exercise capacity but not muscle capillarity in adult mice.

Authors:  Amy E Knapp; Daniel Goldberg; Hamid Delavar; Breanna M Trisko; Kechun Tang; Michael C Hogan; Peter D Wagner; Ellen C Breen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-05-25       Impact factor: 3.619

8.  Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

Authors:  Brian I Rini; Darrel P Cohen; Dongrui R Lu; Isan Chen; Subramanian Hariharan; Martin E Gore; Robert A Figlin; Michael S Baum; Robert J Motzer
Journal:  J Natl Cancer Inst       Date:  2011-04-28       Impact factor: 13.506

Review 9.  Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension.

Authors:  Peter Kruzliak; Gabriela Kovacova; Olga Pechanova
Journal:  Angiogenesis       Date:  2012-12-01       Impact factor: 9.596

10.  Tyrosine phosphorylation modulates the vascular responses of mesenteric arteries from human colorectal tumors.

Authors:  Eduardo Ferrero; María Dolores Mauricio; Miriam Granado; Oscar García-Villar; Martín Aldasoro; José María Vila; Manuel Hidalgo; Jorge Luis Ferrero; Nuria Fernández; Luis Monge; Angel Luis García-Villalón
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.